CAMBRIDGE, Mass.–(BUSINESS WIRE)– #datamanagement–Amgen Ventures Invests in TileDB to Advance Their Universal Database. Click here to view original post
CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Jan. 20, 2022 /PRNewswire/ — Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced its lead candidate VT1021 will advance into a Phase 2-3 registrational study through the […]
WALTHAM, Mass.: WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ — Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members […]
Fierce JPM Week: Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen’s Aduhelm aarmstrong Wed, 01/19/2022 – 13:56 Click here to view original post
The former CEO of Constellation Pharmaceuticals Inc. and a former executive of bluebird bio Inc. have both joined the venture capital firm as venture partners. Click here to view original post
Amid increased scrutiny into the close ties between FDA and Biogen prior to the controversial accelerated approval of Aduhelm, the deputy director of the FDA’s office of neuroscience has called it quits after more than […]
Eisai takes baton from Biogen as next Alzheimer’s prospect follows in Aduhelm’s footprints aarmstrong Tue, 01/18/2022 – 21:28 Click here to view original post
Biogen has gone full blitz since Medicare announced it would only cover its new Alzheimer’s drug when used in clinical trials, accusing the agency of discriminating against Alzheimer’s patients and trying to get physicians to […]
CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Jan. 18, 2022 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from the DisTinGuish […]
While much of the pharma industry’s attention pivoted to CMS’ preliminary decision last week to only cover Biogen’s controversial Alzheimer’s drug Aduhelm in clinical trials and its effect on prescribing, neurologists were already hesitant. Spherix […]
© 2021 Biotech Networks, LLC
